US22407B1089
© BusinessWire
09.12.2025
COYA
LISTED
NASDAQ
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced that dosing of ALS patients in the Company’s ALSTARS Trial of COYA 302 has commenced.
Dr. Fred Grossman, the...
Themefolio
Profiler
Peergroup
© BusinessWire
25.11.2025
COYA
LISTED
NASDAQ
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces the company’s management team will participate in two upcoming conferences.
8th Annual Evercore Healthcare C...
Themefolio
Profiler
Peergroup
© BusinessWire
12.11.2025
COYA
LISTED
NASDAQ
Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, provides a corporate update and announces its financial results for the quarter ended September 30, 2025.
Recent Corporat...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
04.11.2025
COYA
LISTED
NASDAQ
Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today announced results of an in vivo animal study designed to evaluate the effects of COYA 303 (LD IL-2 and GLP-1RA investigational proprietary biologic combination) i...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
27.10.2025
COYA
LISTED
NASDAQ
Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, today announced the closing of its $23.0 million underwritten public offering of 4,181,818 shares of its common stock,...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2025
COYA
LISTED
NASDAQ
Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, today announced that it has priced an underwritten public offering of 3,636,364 shares of its common stock at a public...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2025
COYA
LISTED
NASDAQ
Coya Therapeutics Announces Proposed Public Offering of Common Stock
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Co...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
COYA
LISTED
NASDAQ
Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) congratulates our long-standing scientific advisor, Dr. Shimon Sakaguchi, on being awarded the Nobel Prize for his pioneering discovery of regulatory T cells (Tregs) which protect the body from autoimmune diseases. This discovery has reshaped modern immunology and opened new therapeutic frontiers.
Dr. Sakag...
Themefolio
Profiler
Peergroup
© PR Newswire
29.09.2025
COYA
LISTED
NASDAQ
Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia
News Preview
Following the positive interim results in 5 patients announced earlier this year, a total of 9 patients have been enrolled as planned
The study is progressing according to protocol, and no safety issues have been reported...
Themefolio
Profiler
Peergroup
© PR Newswire
22.09.2025
COYA
LISTED
NASDAQ
Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis
News Preview
The ALSTARS Trial is a well powered randomized, multi-center, double-blind, placebo-controlled, 24-week study of COYA 302 in people with Amyotrophic Lateral Sclerosis (ALS)
Patients completing the initial 24-week treatment will be invited to participate in a 24-week blinded extension period, during which all participants will receive COYA 302
Th...
Themefolio
Profiler
Peergroup
© PR Newswire
16.09.2025
COYA
LISTED
NASDAQ
Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model
News Preview
COYA 303 is an investigational proprietary combination of LD-IL-2 and GLP-1RA for subcutaneous administration, under development for the treatment of diseases, including Alzheimer's Disease, driven by chronic and sustained inflammation;
COYA 303 demonstrated significant attenuation of neuroinflammation in cortex and hippocampus brain regions and...
Themefolio
Profiler
Peergroup
© PR Newswire
04.09.2025
COYA
LISTED
NASDAQ
Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial
News Preview
NEALS, the world's largest ALS research consortium, has selected the COYA 302 trial and it is now affiliated with NEALS as part of its mission to accelerate the development of new treatments for people living with ALS;
Following FDA's recent acceptance of the COYA 302 IND, Coya plans to initiate its Phase 2 study in people with ALS in Q4 2025;
Th...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
03.09.2025
COYA
LISTED
NASDAQ
Coya Therapeutics to Participate at Upcoming September Investor Conferences
News Preview
HOUSTON, Sept. 3, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces the company's management team will participate in two upcoming invest...
Themefolio
Profiler
Peergroup
© PR Newswire
12.08.2025
COYA
LISTED
NASDAQ
Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update
News Preview
HOUSTON, Aug. 12, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, provides a corporate update and announces its financial results for the quarter...
Themefolio
Profiler
Peergroup
© BusinessWire
24.07.2025
COYA
LISTED
NASDAQ
Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson’s Disease
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces the publication of a new research study, partially funded by Coya. The study, led by Drs. Aaron Thome, a scie...
Themefolio
Profiler
Peergroup
© BusinessWire
22.07.2025
COYA
LISTED
NASDAQ
Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that the management team will participate in the BTIG Virtual Biotechnology Conference on July 29 – 30, 2025.
For more information about the BTIG Virtual Bi...
Themefolio
Profiler
Peergroup
© BusinessWire
18.06.2025
COYA
LISTED
NASDAQ
Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. will present at the iAccess Alpha Virtual Best Ideas Summer Conference on Tuesday, June 24, 2025.
Eve...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
COYA
LISTED
NASDAQ
Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya”) today announced the issuance of a U.S. patent relevant to its investigational ready-to-use (RTU) liquid formulation of IL-2. In particular, the U.S. Patent and Trademark Office (USPTO) has granted patent number US 12,312,389 B2, which covers methods of producing highly stable liquid formulations of I...
Themefolio
Profiler
Peergroup
© BusinessWire
16.05.2025
COYA
LISTED
NASDAQ
Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that it will participate in the H.C. Wainwright 3rd Annual BioConnect Conference being held in New York City on Tuesday, May 20, 2025.
Chief Executive Office...
Themefolio
Profiler
Peergroup
© BusinessWire
13.05.2025
COYA
LISTED
NASDAQ
Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update
News Preview
Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended March 31, 2025.
Recent Corporate Highlights
Announced positive interim results...
Themefolio
Profiler
Peergroup
© BusinessWire
08.05.2025
COYA
LISTED
NASDAQ
Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that it will participate in two upcoming conferences in May 2025.
Chief Executive Officer Arun Swaminathan, Ph.D. and Chief Financial Officer David Snyder wi...
Themefolio
Profiler
Peergroup
© BusinessWire
24.04.2025
COYA
LISTED
NASDAQ
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function announced positive interim results of an investigator-initiated proof of concept open-label study with low-dose IL-2 and CTLA4-Ig combination treatment in patients with...
Themefolio
Profiler
Peergroup
© BusinessWire
21.04.2025
COYA
LISTED
NASDAQ
Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today announced publication of the results of a study designed to evaluate the effects of COYA 303 (LD IL-2 and GLP-1RA), Coya’s investigational biologic combination to...
Themefolio
Profiler
Peergroup
© BusinessWire
01.04.2025
COYA
LISTED
NASDAQ
Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that the principal investigator of a low-dose IL-2 Phase 2 study in Alzheimer’s disease (AD), Alireza Faridar, M.D. from Houston Methodist Hospital, will be p...
Themefolio
Profiler
Peergroup
© BusinessWire
26.03.2025
COYA
LISTED
NASDAQ
Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today provides a status update of its investigational regulatory T cell-derived exosome (Treg exosomes) platform intended for the treatment of systemic and neurodegener...
Themefolio
Profiler
Peergroup
© BusinessWire
18.03.2025
COYA
LISTED
NASDAQ
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results
News Preview
Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2024.
Corporate Highlights FY2024 to Date
Announced significant impro...
Themefolio
Profiler
Peergroup
© BusinessWire
25.02.2025
COYA
LISTED
NASDAQ
Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer’s Disease Using GLP-1 Agonists and Combinations
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Dr. Stanley H. Appel, Professor of Neurology, Houston Methodist Hospital will participate in a BTIG h...
Themefolio
Profiler
Peergroup
© BusinessWire
06.02.2025
COYA
LISTED
NASDAQ
Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer’s Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announced encouraging blood biomarker data from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of LD IL-2 in patients w...
Themefolio
Profiler
Peergroup
© BusinessWire
04.02.2025
COYA
LISTED
NASDAQ
Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference being held February 11-12...
Themefolio
Profiler
Peergroup
© BusinessWire
21.01.2025
COYA
LISTED
NASDAQ
Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces the expansion of its investigational pipeline and advancement of COYA 303 for the treatment of inflammatory diseases. Sustained inflammatory responses driven...
Themefolio
Profiler
Peergroup
© BusinessWire
18.12.2024
COYA
LISTED
NASDAQ
Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that five of eight patients have been enrolled in the investigator-initiated academic study of LD IL-2 + CTLA4-Ig combination in patients with Frontotemporal...
Themefolio
Profiler
Peergroup
© BusinessWire
25.11.2024
COYA
LISTED
NASDAQ
Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Executive Chairman Howard Berman, Ph.D. will participate in the 7th Annual Evercore HealthCONx Confer...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2024
COYA
LISTED
NASDAQ
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan.
Dear Fellow Stockholder,
Given my recent transition to the role of CEO, I wanted to sha...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2024
COYA
LISTED
NASDAQ
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results
News Preview
Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended September 30, 2024.
Recent Corporate Highlights
Announced positive results from...
Themefolio
Profiler
Peergroup
© BusinessWire
01.11.2024
COYA
LISTED
NASDAQ
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that, as previously disclosed, Arun Swaminathan, Ph.D., has been promoted to Chief Executive Officer, effective today, November 1, 2024. Dr. Swaminathan was i...
Themefolio
Profiler
Peergroup
© BusinessWire
28.10.2024
COYA
LISTED
NASDAQ
Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces it will conduct a conference call on Tuesday, October 29, at 8am ET to discuss results from a placebo-controlled, investigator-initiated Phase 2 clinical tria...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2024
COYA
LISTED
NASDAQ
Coya Therapeutics Announces Closing of $10.0 Million Private Placement
News Preview
Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of regulatory T cells (“Tregs”), announced today the closing of the sale of an aggregate of 1,379,314 shares of its common stock in a private placement at a price of $7.25...
Themefolio
Profiler
Peergroup
© BusinessWire
22.10.2024
COYA
LISTED
NASDAQ
Coya Therapeutics Announces $10.0 Million Private Placement
News Preview
Coya Therapeutics, Inc. (Nasdaq:COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of regulatory T cells (“Tregs”), announced today that it has entered into definitive securities purchase agreements for the purchase and sale of an aggregate of 1,379,314 s...
Themefolio
Profiler
Peergroup
© BusinessWire
08.10.2024
COYA
LISTED
NASDAQ
Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chairman and CEO Howard Berman, Ph.D. has been recognized as a PharmaVoice 100 winner in the category of Biotech Pathfinders. The annual list recognizes...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2024
COYA
LISTED
NASDAQ
Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that CEO Howard Berman, Ph.D. and Chief Business Officer and incoming Chief Executive Officer Arun Swaminathan, Ph.D, will participate in a fireside chat at t...
Themefolio
Profiler
Peergroup
© BusinessWire
16.09.2024
COYA
LISTED
NASDAQ
Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces the direct CNS anti-inflammatory effect of subcutaneously administered COYA 302 in a preclinical inflammatory associated mouse model of Parkinson’s Disease (P...
Themefolio
Profiler
Peergroup
© BusinessWire
03.09.2024
COYA
LISTED
NASDAQ
Coya Therapeutics to Present at Upcoming Healthcare Conferences
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that CEO Howard Berman, Ph.D. will present at two upcoming healthcare conferences.
On September 26, 2024, Dr. Berman will participate in a panel discussion...
Themefolio
Profiler
Peergroup
© BusinessWire
19.08.2024
COYA
LISTED
NASDAQ
Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today announced that Arun Swaminathan Ph.D. has been promoted to the role of Chief Executive Officer effective November 1, 2024. He will succeed Dr. Howard Berman who w...
Themefolio
Profiler
Peergroup
© BusinessWire
12.08.2024
COYA
LISTED
NASDAQ
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results
News Preview
Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended June 30, 2024.
Recent Corporate Highlights
Presented updated biomarker data i...
Themefolio
Profiler
Peergroup
© PR Newswire
13.03.2024
COYA
LISTED
NASDAQ
Thinking about buying stock in Vale SA, Virpax Pharmaceuticals, Paymentus, Futu Holdings, or Coya Therapeutics?
News Preview
NEW YORK, March 13, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VALE, VRPX, PAY, FUTU, and COYA.
To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObser...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
